Navigation Links
Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
Date:11/11/2008

ts observed in one study or using one type of product or procedure will be replicated in subsequent studies or in studies using newly-developed products or procedures, that planned product development efforts and clinical studies can be performed in an efficient and effective manner, that regulatory approvals can be obtained in a timely manner or at all, that partnering, distribution or other commercialization efforts can be achieved and if so that they will effectively accelerate InnerCool's patient temperature modulation business or market, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that our products or proposed products will prove to be sufficiently safe and effective, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of therapeutic hypothermia devices and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new devices and systems and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical pe
'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
3. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
6. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
7. China Biologic Products Announces Third Quarter 2008 Results Conference Call
8. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
9. Heritage Labs Announces A1c Test Certification Milestone
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. The Binding Site Announces Trading Update for Year Ended September 30th 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... September 16, 2014 Cancer ... and Adoptive T-cell Therapies is a new market ... on the three principal types of therapeutics that ... development in cancer immunotherapy (which is often called ... vaccines and Adoptive cellular immunotherapy. , The ...
(Date:9/15/2014)... Sept. 15, 2014  FlexTech Alliance today issued ... printed product demonstrators (demos) and a functional electronic ... with pre-proposals due on October 22, 2014 and ... proposals ultimately selected are provided by the US ... cost share by the proposing organization. ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)... of researchers led by Northeastern University has developed ... junctions and a variety of nanocarbon structures in ... easily scalable, which will allow the researchers to ... use in applications ranging from electronic devices to ... to sports equipment. , Their findings were published ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... Cambrex (NYSE:,CBM), a leading life sciences company, announced today ... and Chief Executive Officer,and a member of the Cambrex ... Mack, President and Chief Executive Officer since 1995,and Chairman ... Company will,separate the positions of Board Chairman and CEO ...
... PRINCETON, N.J., May 15 Derma Sciences, Inc.,(OTC Bulletin ... today for the first quarter ended March 31, 2008. ... previous year, including sales,from the newly acquired First Aid ... due primarily to higher than expected,integration costs associated with ...
... supply of top-quality custom cosmesis, hires U.S. ... sales and marketing ... /PRNewswire/ - Touch,Bionics, developer of the i-LIMB Hand, the world,s ... the complete operations of LIVINGSKIN, the developer of the unique,and ...
Cached Biology Technology:Cambrex Appoints Steven M. Klosk as President and CEO 2Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5Touch Bionics acquires LIVINGSKIN 2Touch Bionics acquires LIVINGSKIN 3
(Date:9/15/2014)... naturally across all kingdoms of life and constitute a ... of biological activities. The presence of halogen substituents in ... molecular properties. , One of the Holy ... late-stage, site-specific incorporation of a halogen atom into a ... (one of the most inert chemical bonds known in ...
(Date:9/15/2014)... Australia,s leading coral reef ecologists fears that reef biodiversity ... survival that we once thought. , In an international ... Centre of Excellence for Coral Reef Studies (Coral CoE) ... important species within reef ecosystems. , In coral reefs, ... jobs that keep the ecosystem safe and functioning. ...
(Date:9/15/2014)... of Science and Technology in Society in the College ... has won a 2014 National Science Foundation Faculty Early ... of creating a global nuclear emergency response plan. , ... Plant in March 2011 was a turning point in ... Three of the plant,s six nuclear reactors melted down ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2Specialized species critical for reefs 2'Nuclear disasters don't respect national boundaries' 2
... State University have discovered a new method to speed ... advance that could play an important role in making ... an arrayed microchannel reactor and a "laminated architecture" in ... them, are stacked in parallel to provide a high ...
... the first time, completely characterized an important chemical reaction that ... areas. The team,s results indicate that computer models may be ... air quality (smoggy days) by as much as five to ... to people, animals and plants; is the primary ingredient of ...
... made by researchers at the Institut de recherches cliniques ... Noia, Director of the Mechanisms and Genetic Diversity research ... of Experimental Medicine . The team identified a mechanism ... the therapy of some types of lymphoma and leukemia. ...
Cached Biology News:Microreactor speeds nanotech particle production by 500 times 2Study improves accuracy of models for predicting ozone levels in urban areas 2Study improves accuracy of models for predicting ozone levels in urban areas 3Study improves accuracy of models for predicting ozone levels in urban areas 4A discovery could be important for the therapy of lymphoma and leukemia 2
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
Biology Products: